Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

I

IGM Biosciences

Status and phase

Enrolling
Phase 1

Conditions

Solid Tumor
Chondrosarcoma
Sarcoma
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma
Acute Myeloid Leukemia
Colorectal Cancer

Treatments

Drug: Bevacizumab (and approved biosimilars)
Drug: FOLFIRI
Drug: Docetaxel
Drug: Venetoclax
Drug: Aplitabart (IGM-8444)
Drug: Birinapant
Drug: Azacitidine
Drug: Gemcitabine

Study type

Interventional

Funder types

Industry

Identifiers

NCT04553692
IGM-8444-001

Details and patient eligibility

About

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of aplitabart+FOLFIRI+bevacizumab.

Full description

Participants will be enrolled in Phase 1a, which consists of two stages: a dose-escalation stage and an expansion stage. Aplitabart will be used as a single agent and in combination with numerous other agents where standard therapeutic regimens do not exist, have proven to be ineffective or intolerable, or are considered inappropriate. Colorectal participants may be enrolled in Phase 1b, an open-label, randomized study of aplitabart+FOLFIRI+ bevacizumab. Aplitabart will be investigated in numerous tumor types including all-comers solid tumors, colorectal carcinoma (CRC), sarcoma, non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). Aplitabart will be administered intravenously (IV). An alternative dosing schedule may be evaluated.

Enrollment

430 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Age ≥ 18 years at time of signing ICF
  • ECOG Performance Status of 0 or 1
  • Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts.
  • Adequate hepatic and renal function and adequate bone marrow reserve function.
  • For combination cohorts, participants must be eligible to receive the chemotherapy or targeted agent.
  • Ph1a only: No more than three prior therapeutic regimens.
  • Ph1b only: Must be FOLFIRI naïve participants and must have received only 1 prior therapeutic regimen administered for the treatment of cancer in the advanced/metastatic setting - OR - FOLFIRI naïve participants that only received adjuvant therapy who progressed within six months after completing adjuvant therapy, and are confirmed to have locally advanced/metastatic disease

Key Exclusion Criteria:

  • Inability to comply with study and follow-up procedures.
  • Prior DR5 agonist therapy.
  • Concomitant use of agents well-known to cause liver toxicity.
  • Concomitant use of anti-cancer agents
  • Palliative radiation to bone metastases within 2 weeks prior to Day 1.
  • Major surgical procedure within 4 weeks prior to Day 1.
  • Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Participants with a history of treated CNS metastases are eligible.
  • Prior use of any chemotherapeutic agent or small molecule inhibitors (SMI) within 2 weeks or 5 half-lives, prior to the first dose of study treatment
  • Treatment with a monoclonal antibody, or any other anticancer agent (including biologic, experimental, or hormonal therapy) investigational or otherwise, that is not chemotherapy or a SMI, within 4 weeks or five half-lives prior to first dose of study treatment.
  • Ph1b: Participants who have previously received FOLFIRI treatment in the adjuvant, advanced, or metastatic disease setting

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

430 participants in 8 patient groups

Ph1a: Aplitabart Single Agent Alternate Dosing Escalation
Experimental group
Description:
Aplitabart will be administered intravenously as a single agent on an alternate dosing schedule.
Treatment:
Drug: Aplitabart (IGM-8444)
Ph1a: Aplitabart + FOLFIRI ± bevacizumab Escalation and Expansion
Experimental group
Description:
Aplitabart will be administered intravenously in combination with FOLFIRI± bevacizumab.
Treatment:
Drug: Aplitabart (IGM-8444)
Drug: FOLFIRI
Drug: Bevacizumab (and approved biosimilars)
Ph1a: Aplitabart + Birinapant Escalation and Expansion
Experimental group
Description:
Aplitabart will be administered intravenously in combination with Birinapant which will also be administered intravenously.
Treatment:
Drug: Birinapant
Drug: Aplitabart (IGM-8444)
Ph1a: Aplitabart + Venetoclax Escalation and Expansion
Experimental group
Description:
Aplitabart will be administered intravenously in combination with Venetoclax.
Treatment:
Drug: Aplitabart (IGM-8444)
Drug: Venetoclax
Ph1a: Aplitabart + Docetaxel + Gemcitabine Escalation and Expansion
Experimental group
Description:
Aplitabart will be administered intravenously in combination with Docetaxel and Gemcitabine.
Treatment:
Drug: Gemcitabine
Drug: Aplitabart (IGM-8444)
Drug: Docetaxel
Ph1a: Aplitabart + Venetoclax + Azacitidine Escalation and Expansion
Experimental group
Description:
Aplitabart will be administered intravenously in combination with Venetoclax and Azacitidine.
Treatment:
Drug: Azacitidine
Drug: Aplitabart (IGM-8444)
Drug: Venetoclax
Ph1b: Aplitabart + FOLFIRI + Bevacizumab
Experimental group
Description:
Aplitabart will be administered intravenously in combination with FOLFIRI + bevacizumab
Treatment:
Drug: Aplitabart (IGM-8444)
Drug: FOLFIRI
Drug: Bevacizumab (and approved biosimilars)
Ph1b: FOLFIRI + Bevacizumab
Experimental group
Description:
Standard of Care FOLFIRI + bevacizumab will be administered intravenously
Treatment:
Drug: FOLFIRI
Drug: Bevacizumab (and approved biosimilars)

Trial contacts and locations

58

Loading...

Central trial contact

Clinical Trials

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems